Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (186)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

    Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

  3. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  4. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

  5. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    New England Journal of Medicine, Vol. 390, Núm. 4, pp. 301-313

  6. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  7. High adherence to Western dietary pattern increases breast cancer risk (an EPIC-Spain study)

    Maturitas, Vol. 179

  8. Lessons learned from self-efficacy of healthcare professionals for advance care planning

    Palliative Medicine in Practice, Vol. 18, Núm. 1, pp. 15-22

  9. Nomenclature in palliative care and renal support: Not just at the end-of-life

    Nefrologia, Vol. 44, Núm. 4, pp. 475-485

  10. Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors

    Cancer Immunology, Immunotherapy, Vol. 73, Núm. 1

  11. Post- versus intra-operative implant for breast cancer interstitial brachytherapy: How to choose?

    Journal of Contemporary Brachytherapy, Vol. 16, Núm. 1, pp. 72-83

  12. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  13. Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma

    Journal of Personalized Medicine, Vol. 14, Núm. 2

  14. Pseudomonas aeruginosa Bloodstream Infections Presenting with Septic Shock in Neutropenic Cancer Patients: Impact of Empirical Antibiotic Therapy

    Microorganisms, Vol. 12, Núm. 4

  15. Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy

    Clinical and Translational Oncology

  16. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

  17. Status of head and neck brachytherapy in Spain in 2022

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 456-460

  18. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

  19. Very accelerated partial breast irradiation in 1 or 2 days: Late toxicity and early oncological outcome of the GEC-ESTRO VAPBI cohort

    Radiotherapy and Oncology, Vol. 194

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature